Mark S. Ordan Sells 27,600 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Pediatrix Medical Group Stock Down 1.1 %

MD traded down $0.16 during trading on Friday, hitting $14.60. The stock had a trading volume of 43,385 shares, compared to its average volume of 864,096. The company has a 50 day moving average price of $12.46 and a 200-day moving average price of $9.81. Pediatrix Medical Group, Inc. has a one year low of $6.62 and a one year high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 EPS. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. UBS Group lifted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday. Jefferies Financial Group boosted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Mizuho lifted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $16.10.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors have recently modified their holdings of the business. Centiva Capital LP increased its stake in shares of Pediatrix Medical Group by 23.7% in the third quarter. Centiva Capital LP now owns 26,717 shares of the company’s stock valued at $310,000 after buying an additional 5,124 shares during the period. ArrowMark Colorado Holdings LLC raised its position in shares of Pediatrix Medical Group by 3.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 787,649 shares of the company’s stock worth $9,129,000 after buying an additional 28,804 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Pediatrix Medical Group by 3.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 237,708 shares of the company’s stock worth $2,755,000 after purchasing an additional 8,609 shares in the last quarter. Rubric Capital Management LP lifted its stake in shares of Pediatrix Medical Group by 1.5% in the 3rd quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock valued at $95,907,000 after acquiring an additional 125,000 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Pediatrix Medical Group by 141.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,520 shares of the company’s stock worth $215,000 after buying an additional 10,843 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.